Melatonin enhances the inhibitory effect of netazumab on glioblastoma by inhibiting EGFR, Melatonin significantly reduces microvascular density and vascular endothelial growth factor (VEGF) expression levels in mouse tumors, inhibiting tumor angiogenesis (Wang et al., 2024). This evidence concerns the gene VEGFA and glioblastoma.